Many of this year’s biopharma M&A deals look promising, including blockbuster match-ups like Pfizer’s $43 billion deal to acquire Seagen to bolster its cancer pipeline, and Merck & Co.’s $10.8 billion acquisition of Prometheus, which could buoy revenue ahead of expected patent losses in years to come. But trying to predict whether an acquisition will lead to a healthy pairing or fall short is difficult. Over the years, the world of pharma and biotech M&A has resulted in many hits and misses — and only with the benefit of hindsight does success or failure become clear.
Read the full article: The Fortunes and Flops of Pharma M&A //
Source: https://www.pharmavoice.com/news/biopharma-deals-merger-acquisition-hit-miss/701330